basic sceince research

MULTI-CENTER NATIONAL DATABASE PROGRAM

CPDR Sites

 

Madigan Army Medical Center, WA

MAJ Timothy Brand, MC, USA, Principal Investigator
Tracy Pletcher, Research Data Manager

 

Naval Medical Center, San Diego, CA

CDR James L'Esperance, MC, USN, Principal Investigator
Audry L'Esperance, Research Data Manager

 

Tripler Army Medical Center, HI

MAJ Joseph Sterbis, MC, USA, Principal Investigator
Joanne Mor, Research Data Manager

 

Virginia Mason Medical Center, WA

Christopher Porter, MD, Principal Investigator
Katherine Levie, Research Data Manager

 

Walter Reed National Military Medical Center, MD

David G. McLeod, MD, JD, Principal Investigator
LTC Inger Rosner, MC, USA, Co-Principal Investigator
Sally Elsamanoudi, MPH, Senior Research Data Manager
Faisal Del, Research Data Manager
Miriam Osman, Research Data Manager

 

MNDP Home | MNDP Staff Listing

CURRENT EVENTS


August 21, 2014

ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical

Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.

Read Full Article

 

August 6, 2014

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints

Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...

Read Full Article

 

WRNMMC UsToo! Newsletter

Read the AUGUST 2014 Newsletter